Case Studies

Streamlining AAV Manufacturing for Clinical Scale-Up

Achieved GMP compliance through advanced optimisation, significantly enhancing yield and accelerating clinical readiness for a European biotech client’s AAV gene therapy.

The Challenge: Achieving GMP Compliance at Scale

A European biotech client developing pre-clinical AAV gene therapies for neurodegenerative diseases needed to scale-up and optimise their initial research process to achieve target dosage and GMP compliance for clinical application.

Our Approach

eXmoor Pharma conducted comprehensive process development, including cell line optimisation, media and filter screening, transfection optimisation, culture condition refinement, and anion exchange chromatography improvements through Design of Experiments (DoE) modelling.

The Outcome

Impact

The optimised, scalable manufacturing process significantly accelerated the client’s progression to clinical trials, supporting timely clinical development milestones.

Let’s Accelerate Your Therapy Together

Whether you’re in early-stage development or scaling up for commercial production, eXmoor Pharma provides the expertise and flexibility you need. Partner with us to move your therapy forward with confidence.